Plain-English translation of NCT07005180 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , an oral liquid medication containing low-dose carbon monoxide, to see if it is safe and how your body handles it in people with Parkinson's disease. About 36 participants will take either the medication at one of two doses or a placebo (a dummy pill with no active ingredient) every day for 14 days. The study will measure safety, how well the treatment is tolerated, and how the body processes the medication.
Researchers are exploring whether this medication might help protect brain cells or reduce inflammation in Parkinson's disease, which could potentially slow or improve symptoms. This early-stage study will help determine if this treatment is safe enough and promising enough to test further in larger groups of patients.
You likely qualify if…
You likely don't qualify if…
You will visit the study clinic for screening and baseline tests, which include blood work and heart monitoring to make sure you are healthy enough to participate. Then you will take the medication or placebo by mouth once daily at home for 14 days while a study partner observes you for safety. You will have follow-up visits to check how you are doing and provide blood samples so researchers can measure how your body handles the medication.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States